Home > Insider Trading > Filing (0001209191-19-025794)

Filing Details

Accession Number:: 0001209191-19-025794
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-04-24 18:16:20
Reporting Period:: 2019-04-22

Accepted Time:: 2019-04-24 18:16:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1595893	Turning Point Therapeutics Inc.	TPTX	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	C/O Turning Point Therapeutics, Inc. 10628 Science Center Drive, Ste. 225 San Diego CA 92121		Yes	No	No	No
1682115	Orbimed Capital Gp Vi Llc	C/O Turning Point Therapeutics, Inc. 10628 Science Center Drive, Ste. 225 San Diego CA 92121		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-04-22	1,120,730	$0.00	1,120,730	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-04-22	546,820	$0.00	1,667,550	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-04-22	360,000	$18.00	2,027,550	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2019-04-22	4,314,809	$0.00	1,120,730	$0.00
Common Stock	Series D Preferred Stock	Disposition	2019-04-22	2,105,259	$0.00	546,820	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date.
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VII") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein.
This report on Form 4 is jointly filed by GP VI and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange At of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently Carl L. Gordon ("Gordon"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
The shares were purchased at the Issuer's initial public offering.